Introduction
============

Colorectal cancer is a group of distinct diseases rather than a homogeneous one[@B1]. The colon can be divided into left and right sides with the splenic flexure as the boundary[@B2]. Various evidences suggest that left-side colon cancer differs significantly from right-side colon cancer in terms of risk factors, histological grade, tumor size and metastatic features[@B3], [@B4]. Indeed, different molecular characteristics exist between right-side colon and left-side colon, as well as rectum[@B5]. What\'s more, clinical evidence supports that right-side and left-side colon cancers response differently to palliative chemotherapy, as well as cetuximab[@B4], [@B6]-[@B8]. When it comes to anti-angiogenic therapy, Boisen et al. reported that patients with tumors originating from sigmoid colon or rectum had better survival than those from cecum to descending colon when treated with capecitabine and oxaliplatin (CAPEOX) plus bevacizumab (median OS were 23.5 versus 13.0 months), and the survival advantage disappeared when patients were treated with CAPEOX without bevacizumab[@B9]. However, Fotios et al. reported a study which failed to validate the correlation since both primary tumor location and bevacizumab use were independent factors in multivariable analyses[@B10], [@B11]. Venook et al. reported that bevacizumab was superior to cetuximab in right-side colon cancer patients[@B12]. Given all of these inconsistent results, in this study we evaluated the prognostic impact of primary tumor location on survival of mCRC patients, as well as the predictive value of primary tumor location on bevacizumab effectiveness. We also performed propensity score analyses to reduce the impact of clinical and pathological features which distributed differently between right-side and left-side colon.

Materials and Methods
=====================

Data source and patient selection
---------------------------------

From January 2005 to December 2013, we retrospectively recruited consecutive patients with histologically proven mCRC at Sun Yat-sen University Cancer Center. The study was approved by the Ethics Committee of Sun Yat-sen University Cancer Center, and informed consent was obtained from every patient. Patients who accepted at least three cycles palliative chemotherapy were included. Exclusion criteria were as follows: 1) case history not available; 2) without follow up information; 3) with cetuximab as first-line treatment; 4) with other coexisting malignancy.

Date analyses and statistics
----------------------------

Right-sided colon cancers included those occurring in cecum, ascending colon or transverse colon. Left sided colon cancers included those occurring in descending or sigmoid colon. All patients were grouped into chemotherapy group (CT group) or chemotherapy + bevacizumab group (CT + B group) according to the first-line treatment. We also performed propensity score analyses to adjust for heterogeneity since several clinical and pathological features were not balanced when patients were grouped by primary tumor location. As previously reported[@B13], we performed a 1:1 propensity score analyses by modeling logistic regression with balanceable variables, including gender, mucinous histology, stage at diagnosis and LDH levels. The matching tolerance for propensity score analyses was 0.001. The primary endpoint of this study was overall survival (OS), defined as the time from the establishment of metastatic or recurrent disease to the date of death or the last follow-up. Follow-up information was updated in 30th December 2015. We called all the patients or their family members through the phone numbers they left at our hospital. All statistical analyses were performed with the SPSS software version 22. The differences in survival were compared by Kaplan-Meier analyses and log-rank test. Multivariate analysis using a Cox proportional hazards model was used to test independent significance by backward elimination of insignificant explanatory variables. A two-tailed *p* value less than 0.05 was considered statistically significant.

Results
=======

The study flowchart is shown in Figure [1](#F1){ref-type="fig"}. 984 patients were included in the study. The median follow-up period was 22 months; during this follow-up period, 624 deaths (63.4%) were documented. The median OS of all patients was 21.8 months. The study comprised 740 patients in CT group and 244 patients in CT + B group. The distributions of primary tumor location as well as other characteristics were shown in the Table [1](#T1){ref-type="table"}. The distributions of most characteristics were similar, except gender, mucinous histology, stage at diagnosis, and lactate dehydrogenase (LDH) levels. In all patients, bevacizumab was associated with longer OS (*p*=0.001, Figure [2](#F2){ref-type="fig"}a).

No evidence of difference was found in survival outcome for different primary tumor location in CT group. Median OS for right-side colon, left-side colon and rectal cancer patients were 19.7, 22.3 and 21.1 months, respectively (*p*=0.466, Figure [2](#F2){ref-type="fig"}b). However, significant differences were detected in OS according to primary tumor location in CT + B group. Median OS for patients with right-side colon, left-side colon and rectal cancer patients were 20.2, 26.3 and 26.4 months, respectively (*p*=0.021, Figure [2](#F2){ref-type="fig"}c). The detailed differences of CT + B group in left and right side colon were shown in Table [2](#T2){ref-type="table"}. Multivariate analysis including primary tumor location, primary tumor resection, number of metastatic organ, LDH and CEA levels confirmed that primary tumor location was an independent factor (hazard ratio 0.765, 95 % confidence interval 0.607-0.966, *p* =0.024) in CT + B group.

To further evaluate the predictive value of primary tumor location in regards to bevacizumab effectiveness, we studied whether the treatment benefit of bevacizumab differed among three primary tumor locations. Patients with right-side colon cancer had similar OS (19.7 months vs 20.2 months, *p*=0.556, Figure [2](#F2){ref-type="fig"}d) comparing CT group with CT + B group. However, patients with left-side colon cancer could derive benefit from bevacizumab (median OS was 26.3 months for CT+B group and 22.3 months for CT group, *p*=0.021, Figure [2](#F2){ref-type="fig"}e). Significant longer OS were also detected in rectal cancer patients when bevacizumab were added (median OS was 26.4 months for CT+B group and 21.1 months for CT group, *p*=0.006, Figure [2](#F2){ref-type="fig"}f). The routinely clinical-pathological factors were comparable in those comparisons.

Since gender, mucinous histology, stage at diagnosis and LDH levels were not balanceable, we performed propensity score analyses to adjust for those heterogeneities, as shown in the Table [3](#T3){ref-type="table"}. Similar results were observed after matching. 58 right-side colon, 86 left-side colon and 99 rectal cancer patients were included in CT group (total: 243) while 78 right-side colon, 86 left-side colon and 80 rectal cancer patients were included in CT + B group (total: 244). For patients in CT group, median OS for right-side colon, left-side colon and rectal cancer patients were 20.4, 23.1 and 21.2 months, respectively (p=0.800). Patients in CT + B group had a similar OS in comparison with CT group only when the primary tumor located at right-side colon (median OS were 20.2 months for CT + B group versus 20.5 for CT group, *p* = 0.851). For left-side colon cancer patients, those in CT + B group had longer OS than CT group (26.3 versus 23.1 months, P = 0.021). For rectal cancer patients, significantly longer OS were also observed in CT + B than CT group (26.3 versus 21.1 months, *p* = 0.014).

Discussion
==========

In this study, we observed that survival was inferior for right-side as compare to left-side colon or rectal cancer patients when they were treated with chemotherapy plus bevacizumab. Since right-side colon cancer has prevalence toward being mucinous type and more advanced disease, we also performed propensity score analyses to reduce the impact of its nature. What\'s more, in patients treated with chemotherapy plus bevacizumab, we conducted multivariate analysis to confirm that primary tumor location was an independent factor. At last, we compared the survival between patients who accepted chemotherapy alone and chemotherapy plus bevacizumab in patients with right-side colon cancer, as well as left-side colon and rectal cancer.

Several other studies were in line with the present study. Boisen reported the prognostic value of primary tumor location when mCRC patients were treated with CAPEOX plus bevacizumab, and the prognostic value of primary tumor location disappeared when patients were treated with CAPEOX only[@B9]. Brule et al. reported that tumor location within the colon is not prognostic in NCIC CO.17 trial, in which patients were treated with cetuximab versus best supportive care, [@B14]. In Brule\'s study, the the primary tumor location was not with prognostic values for OS (HR 0.96 \[0.70-1.31\], p = 0.78) or progression-free survival (HR 1.07 \[0.79-1.44\], p = 0.67). Together, these reports and our study make the interaction between bevacizumab effectiveness and primary tumor location less likely to be a coincidence.

One possible reason underlying the interaction between primary tumor location and bevacizumab effectiveness is that VEGF-A, the target of bevacizumab, is higher expressed in left-side colon and rectum than right-side colon[@B15]. Volz et al. also reported that germline polymorphisms related to pericyte maturation, which could predict treatment benefit of bevacizumab, was dependent on primary tumor location[@B16]. However, the exact mechanism underlying this interaction remains exclusive.

Our study has several implications. We suggest that investigators should consider the primary tumor location as a stratification factor in designing or reviewing clinical studies involving bevacizumab. In addition, primary tumor location of mCRC should be considered when cetuximab and bevacizumab are compared, since right-side and left-side mCRC patients also respond differently to cetuximab. Indeed, Venook et al. reported that bevacizumab might be superior to cetuximab for right-sided mCRC[@B12]. We think their results were not contradicted with our study since we compared chemotherapy plus bevacizumab with chemotherapy only, with first-line cetuximab excluded.

There are several limitations of this study. First, the retrospective nature limited its power. Second, several molecular features were not available, such as kirsten rat sarcoma viral oncogene homolog (KRAS) status. Third, we did not compare progression free survival since we could not determine the precise time of tumor progression based on medical records. Those limitations should be considered when interpreting our study.

In conclusion, our data suggest that primary tumor location is a prognostic factor for mCRC patients when treated with bevacizumab, and patients with right-side colon cancer cannot get survival benefit from the addition of bevacizumab to first-line chemotherapy. Further data from randomized trials are needed to test our hypothesis.
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###### 

The characteristics of patients.

                                  All patients                     
  ------------------------------- -------------- ----- ----- ----- -----------
  Number of patients              984            300   345   339   
  Age                                                              
  ≤50 y                           387            120   138   129   0.934
  51-65 y                         387            120   131   136   
  \>65 y                          210            60    76    74    
  Gender                                                           
  Male                            637            177   228   203   *0.036*
  Female                          347            123   117   107   
  Mucinous histology                                               
  Yes                             158            69    49    40    *\<0.001*
  No                              826            231   296   299   
  Stage at diagnosis                                               
  I                               8              1     2     5     *\<0.001*
  II                              70             20    20    30    
  III                             206            48    56    102   
  IV                              700            231   267   202   
  First line therapy                                               
  Chemotherapy                    740            222   259   259   0.685
  Bevacizumab + chemotherapy      244            78    86    80    
  Metastatic organ                                                 
  1                               714            221   251   242   0.808
  \>1                             270            79    94    97    
  CEA                                                              
  ≤5 ng/ml                        275            81    92    102   0.563
  \>5 ng/ml                       702            217   250   235   
  unknown                         7              2     3     2     
  LDH                                                              
  ≤245 U/ml                       702            228   230   244   *0.035*
  \>245 U/ml                      279            71    113   95    
  unknown                         3              1     2           
  Backbone chemotherapy                                            
  Oxaliplatin-based               682            213   244   225   0.685
  Irinotecan-based                257            73    87    97    
  5-fluorouracil only             45             14    14    17    
  Bevacizumab beyond first line                                    
  Yes                             83             26    31    26    0.813
  No                              901            274   314   313   
  Cetuximab treated                                                
  Yes                             104            29    40    35    0.637
  No                              880            271   304   304   
  Primary tumor resection                                          
  Yes                             606            186   220   200   0.432
  No                              378            114   125   139   

###### 

Patient characteristics in the chemotherapy + bevacizumab group.

  Variable                        Right-side colon   Left-side colon   *P*-value, chi-square
  ------------------------------- ------------------ ----------------- -----------------------
  Number of patients              78                 86                
  Age                                                                  
  ≤50 y                           41                 41                0.598
  51-65 y                         25                 34                
  \>65 y                          12                 11                
  Sex                                                                  
  Male                            44                 56                0.266
  Female                          34                 30                
  Mucinous histology                                                   
  Yes                             15                 14                0.684
  No                              63                 72                
  Stage at diagnosis                                                   
  I                               1                  9                 0.207
  II                              6                  24                
  III                             26                 53                
  IV                              45                 86                
  Metastatic organ                                                     
  1                               59                 61                0.597
  \>1                             19                 25                
  CEA                                                                  
  ≤5 ng/ml                        15                 28                0.051
  \>5 ng/ml                       63                 56                
  unknown                         0                  2                 
  LDH                                                                  
  ≤245 U/ml                       57                 57                0.494
  \>245 U/ml                      21                 28                
  unknown                         0                  1                 
  Backbone chemotherapy                                                
  Oxaliplatin-based               41                 49                0.304
  Irinotecan-based                37                 35                
  5-fluorouracil only             0                  2                 
  Bevacizumab beyond first line                                        
  Yes                             16                 15                0.691
  No                              62                 71                
  Cetuximab treated                                                    
  Yes                             7                  13                0.245
  No                              71                 73                
  Primary tumor resection                                              
  Yes                             57                 67                0.585
  No                              21                 19                

###### 

The characteristics of patients after propensity score analyses.

                                  Propensity score-matched patients                     
  ------------------------------- ----------------------------------- ----- ----- ----- -----------
  Number of patients              487                                 136   172   179   
  Age                                                                                   
  ≤50 y                           230                                 67    85    78    0.787
  51-65 y                         176                                 46    61    69    
  \>65 y                          81                                  23    26    32    
  Gender                                                                                
  Male                            302                                 78    107   117   0.348
  Female                          185                                 58    65    62    
  Mucinous histology                                                                    
  Yes                             81                                  27    30    24    0.295
  No                              406                                 109   142   155   
  Stage at diagnosis                                                                    
  I                               6                                   1     1     4     *\<0.001*
  II                              48                                  13    11    24    
  III                             163                                 39    47    77    
  IV                              270                                 83    113   74    
  First line therapy                                                                    
  Chemotherapy                    243                                 58    86    99    0.084
  Bevacizumab + chemotherapy      244                                 78    86    80    
  Metastatic organ                                                                      
  1                               345                                 100   115   130   0.662
  \>1                             142                                 36    57    49    
  CEA                                                                                   
  ≤5 ng/ml                        138                                 31    53    54    0.216
  \>5 ng/ml                       346                                 105   117   124   
  unknown                         3                                   0     2     1     
  LDH                                                                                   
  ≤245 U/ml                       346                                 101   114   131   0.262
  \>245 U/ml                      140                                 35    57    48    
  unknown                         1                                   0     1     0     
  Backbone chemotherapy                                                                 
  Oxaliplatin-based               190                                 52    72    66    0.903
  Irinotecan-based                257                                 73    87    97    
  5-fluorouracil only             40                                  11    13    16    
  Bevacizumab beyond first line                                                         
  Yes                             57                                  18    152   160   0.773
  No                              430                                 118   20    19    
  Cetuximab treated                                                                     
  Yes                             55                                  13    21    21    0.655
  No                              432                                 123   151   158   
  Primary tumor resection                                                               
  Yes                             166                                 43    54    69    0.285
  No                              321                                 93    118   110   
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